Banner
Browse by multiple fields below

Download csv Download xlsx
PDX ID Sample ID Patient Id Sample Site Sample Source Age Sample Collected PSA at diagnosis (ng/mL) Gleason Score Primary Gleason Score Secondary Gleason Score Grade Group Tumour Grade D'Amico Risk Classification Primary Tumour Volume (cc) Treatment Prior to Specimen Collection PDX Host Type PDX Graft Site Current PDX Generation Average PDX Generation Time (days ± SEM) Tumour preparation2 Pubmed ID
435.7A 435.7A 435 Front-parietal lobe Autopsy 65-71 16.2 0.0 ADT, carboplatin plus etoposide Testosterone supplemented Subcutaneous 4 57 ± 8 Tumor solid 34413304
435.10A 435.10A 435 Left lateral cerebellum Autopsy 65-72 16.2 0.0 ADT, carboplatin plus etoposide Testosterone supplemented Subcutaneous 4 57 ± 4 Tumor solid 34413304
435.23A 435.23A 435 Right posterior temporal lobe Autopsy 65-73 16.2 0.0 ADT, carboplatin plus etoposide Testosterone supplemented Subcutaneous 4 63 ± 9 Tumor solid 34413304
435.31A 435.31A 435 Right thalamus Autopsy 65-74 16.2 0.0 ADT, carboplatin plus etoposide Testosterone supplemented Subcutaneous 4 53 ± 3 Tumor solid 34413304
435.31A Cx 435.31A 435 Right thalamus Autopsy 65-74 16.2 0.0 ADT, carboplatin plus etoposide Castrate Subcutaneous 7 (3*) 48 ± 1 Tumor solid 34413304
463.8A 463.8A 455/463 Small bowel serosa Autopsy 55-59 7.8 0.0 Radiotherapy, zoladex, docetaxel, enzalutamide, niraparib, cabazitaxel Testosterone supplemented Subcutaneous 6 76 ± 21 Tumor solid 34413304
463.45A 463.45A 455/463 Tumour under diaphragm Autopsy 55-59 7.8 0.0 Radiotherapy, zoladex, docetaxel, enzalutamide, niraparib, cabazitaxel Testosterone supplemented Subcutaneous 7 62 ± 4 Tumor solid 34413304
463.55A 463.55A 455/463 Peritoneal nodule near colon Autopsy 55-59 7.8 0.0 Radiotherapy, zoladex, docetaxel, enzalutamide, niraparib, cabazitaxel Testosterone supplemented Subcutaneous 5 102 ± 16 Tumor solid 34413304